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Primary open-angle glaucoma (POAG) is a complex 
genetic disease and one of the most common causes of visual 
loss worldwide. Mutations in the myocilin gene (MYOC, 
formerly known as the trabecular meshwork-induced gluco-
corticoid response gene) associated with POAG were discov-
ered in 1997 and mapped to the long arm of chromosome 1 
[1]. MYOC variants account for almost 4% of adult POAG 
cases, and 10% of juvenile open-angle glaucoma [2].
POAG attributable to MYOC gene changes is inherited 
in an autosomal dominant manner. Carriers tend to display 
elevated intraocular pressure (IOP) or open-angle glaucoma 
from an early age, although there may be variability in the 
phenotype depending on the underlying mutation [2]. Two 
of the most common glaucoma-causing variants of MYOC 
worldwide are Gln368STOP and Thr377Met [3]. As with 
most disease-causing mutations of this gene, both occur in 
exon 3 [4]. We describe a pedigree that to our knowledge is 
the first identified with individuals compound heterozygous 
for these MYOC mutations.
METHODS
Members of a family with high prevalence of glaucoma were 
recruited into the study. Six individuals living in Australia, 
comprising 4 males and 2 females were available for direct 
clinical examination and genotyping. Five of the patients 
were siblings aged 26 to 35 years. The proband’s mother age 
63 was also assessed. This study was approved by the Human 
Research and Ethics Committee of the Royal Victorian Eye 
and Ear Hospital, Melbourne, and was conducted in accor-
dance with the revised Declaration of Helsinki. Informed 
patient consent was obtained before enrolment.
The proband (patient V:3) was first diagnosed with 
ocular hypertension by her optometrist. She was referred 
to the Australian and New Zealand Registry of Advanced 
Glaucoma (ANZRAG) [5] for MYOC genetic testing due to 
her young age and strong family history of POAG. Following 
identification of the mutations, additional family members 
were ascertained and offered genetic testing through 
ANZRAG after providing signed consent and a blood sample.
First-degree relatives of the index case (patient V:3) lived 
in Australia and were available for direct assessment, except 
the father (patient IV:8), who was deceased. Relatives on the 
father’s side lived in Croatia and were not available for exami-
nation. Comprehensive medical and family history was taken 
by a glaucoma subspecialist ophthalmologist (JBR). Clinical 
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Purpose: To describe the phenotype of ocular hypertension and primary open-angle glaucoma in a family with individu-
als compound heterozygote for Gln368STOP and Thr377Met myocilin (MYOC) mutations.
Methods: Family members of the proband underwent comprehensive ocular clinical examination and DNA sequencing 
for MYOC mutations.
Results: A 34-year-old woman with marked ocular hypertension was found to carry Gln368STOP and Thr377Met MYOC 
mutations. Three other siblings carried both mutations, while one carried Gln368STOP alone. Three of five siblings had 
received treatment for ocular hypertension or early glaucoma, with the average age of diagnosis 28 years; one required 
trabeculectomy at age 27. The mother of the proband was found to be a carrier for Gln368STOP alone, which indicates 
that her offspring with both Gln368STOP and Thr377Met carry variants on opposing alleles.
Conclusions: This pedigree is the first report with individuals compound heterozygote for the two most common 
glaucoma-causing MYOC variants. The combination of mutations manifests a more severe phenotype than either alone. 
Identification of gene changes associated with glaucoma within the family has enabled unaffected members to stratify 
their risk of future disease and institute closer monitoring and early treatment.
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details for disease-affected family members were obtained 
from their medical records, while unaffected individuals 
were invited to present for ocular examination. Data recorded 
included demographic details, general medical history, past 
ocular history, best-corrected visual acuity (BCVA), Gold-
mann IOP, gonioscopy, dilated fundus examination, central 
corneal thickness (Pachmate DGH55, DGH Technology Inc., 
Exton, PA), and Humphrey visual fields (HFA II, Carl Zeiss, 
North Ryde, Australia). For each patient, venous blood was 
collected by peripheral venepuncture in 2×10 ml EDTA tubes. 
The blood samples were stored at 2–8 °C before processing.
The criterion for ocular hypertension was IOP on 
repeated measurement ≥24 mmHg. A diagnosis of POAG was 
made in patients with glaucomatous visual field defects on a 
reliable Humphrey 24–2 field, including an enlarged cup-disc 
ratio (≥0.7) or cup-disc ratio asymmetry (≥0.2) between both 
eyes.
Genotyping: The testing was performed through the National 
Association of Testing Authorities (NATA) accredited labo-
ratories of the Institute of Medical and Veterinary Science 
(IMVS) Pathology at the Flinders Medical Centre (Bedford 
Park, Australia). Genomic DNA was prepared from a 200 μl 
sample of venous blood and extracted using an Illustra Blood 
Genomic Prep Mini Spin kit (GE Healthcare, Buckingham-
shire, UK) according to the manufacturer’s protocols.
Each PCR was performed using 100 ng of purified 
genomic DNA as the template in a reaction mix containing 
1.5 mM MgCl2, 200 μM of each deoxynucleoside triphos-
phate (dNTP), 1 U of Platinum Taq DNA polymerase (Invit-
rogen, Carlsbad, CA), 1x Platinum Taq PCR reaction buffer, 
and 0.5 μM of each primer (for exon 3: 3.1F: 5′-GGG CTG 
TCA CAT CTA CTG GC-3′, 3.1R: 5′-GCT GTA AAT GAC 
CCA GAG GC-3′; 3.2F: 5′-GCT GAA TAC CGA GAC AGT 
GAA G-3′, and 3.2R: 5′-AAC TTG GAA AGC AGT CAA 
AGC-3′), in a final volume of 25 μl. Samples were denatured 
for 5 min at 94 °C and then incubated for 15 cycles under the 
following conditions: 94 °C for 30 s, 61 °C for 50 s (reduced 
1 °C every five cycles), and 72 °C for 60 s. The samples were 
then incubated for 35 cycles under the following conditions: 
94 °C for 30 s, 58 °C for 50 s, and 72 °C for 60 s. The last 
elongation step was at 72 °C for 5 min on a Veriti thermal 
cycler (Life Technologies, Carlsbad, CA).
PCR amplicons were prepared for DNA sequencing with 
the ExoSAP method using a 10 μl sample of each PCR reac-
tion treated with 5 U of Exonuclease I (New England Biolabs, 
Ipswich, MA) and 1 U of Shrimp Alkaline Phosphatase (USB) 
to remove residual primers and deoxynucleoside triphosphate 
(dNTPs). Bidirectional BigDye Terminator Cycle Sequencing 
(Life Technologies) reactions of the appropriate template and 
exon 3 MYOC PCR primer were resolved and base called 
on an Applied Biosystems 3130XL Genetic Analyzer (Life 
Technologies).
Detection of sequence variants was performed with the 
Mutation Surveyor v3.10 (SoftGenetics LLC, State College, 
PA) software; all forward and reverse sequence trace files 
for overlapping upstream and downstream PCR fragments 
of exon 3 were assembled by the software into a single 
contiguous sequence following alignment against the MYOC 
gene GenBank reference NM_000261.1. Significant differ-
ences in the relative peak heights of the sequence traces 
observed between that of the patient sample and a normal 
control were automatically called a sequence variant by 
Mutation Surveyor; all such calls were visually inspected for 
confirmation.
RESULTS
The entire pedigree of this MYOC glaucoma family is 
shown in Figure 1. There are six generations with 46 known 
members. The family of the proband’s mother (patient IV:9) 
were Dutch, while the father (patient IV:8) was of Croatian 
ancestry.
Clinical data of examined family members are summa-
rized in Table 1. All patients had open anterior chamber 
angles bilaterally with gonioscopy. The average age at diag-
nosis for individuals with POAG or ocular hypertension was 
28 years.
The most severe phenotype is exhibited in patient V:6. 
This patient presented with a right ischemic central retinal 
vein occlusion and elevated IOP in both eyes at age 25. He 
subsequently developed anterior chamber angle neovasular-
ization requiring treatment with indirect scatter laser photo-
coagulation and intravitreal bevacizumab. The patient’s blood 
pressure was normal, and physician evaluation for a hyperco-
agulable state unremarkable. The only identified risk factor 
for the central retinal vein occlusion was ocular hypertension.
Fundus examination showed a cup-disc ratio of 0.5 in the 
right eye and 0.4 in the left with normal neuroretinal rims in 
both (Figure 2A). Visual field testing was normal in the left 
eye, but showed an arcuate loss in the right, likely due to the 
panretinal photocoagulation (Figure 2B).
Two years after his initial treatment, his right IOP 
became uncontrolled on medical treatment alone, and he 
proceeded to trabeculectomy with mitomycin C. His IOP is 
also poorly controlled in the left eye despite the use of three 
antiglaucoma medications, and glaucoma surgery has been 
recommended.
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The proband’s mother had no evidence of ocular hyper-
tension or glaucoma at age 63. Her seven siblings (ranging 
from 59 to 73 years old) have refused examination, but are 
all believed to be unaffected.
The proband’s father was diagnosed with glaucoma at 
age 45 years (patient IV:8). On this side of the family, nine of 
28 individuals were known to have POAG or thought to have 
glaucoma based on reports of previous eye surgery.
Analysis of the MYOC gene in the proband (patient V:3) 
showed a heterozygous C>T substitution at nucleotide 1102 
in exon 3, predicted to generate a nonsense codon in place of 
the normal glutamine codon at position 368 (Gln368STOP). 
In addition, a second DNA sequence variant was discovered: 
a heterozygous C>T substitution at nucleotide 1130 in exon 3, 
predicted to generate a missense substitution of methionine 
for threonine normally present at codon 377 (Thr377Met).
Four of five children were carriers of both Gln368STOP 
and Thr377Met (Figure 1). Of these, three had already been 
diagnosed with glaucoma or ocular hypertension (ages 25, 
26, and 34).
Genotyping could not be performed on the proband’s 
father as the patient was deceased. The unaffected mother 
(patient IV:9) was found to carry the Gln368STOP mutation. 
One of her brothers was screened for the Gln368STOP muta-
tion and does not carry it. The rest of her siblings have not 
requested genetic testing.
DISCUSSION
To date, more than 80 disease-causing MYOC variants have 
been identified [3]. Gln368STOP and Thr377Met are the two 
most common worldwide [4]. We present here the first report 
of glaucoma-affected individuals carrying both variants. 
In this pedigree, the proband’s mother (patient IV:9, Figure 
1) carries the Gln368STOP mutation alone; therefore, we 
concluded that the Thr377Met variant was passed down from 
the proband’s father (patient IV:8) and that children with both 
would carry mutations on opposing alleles.
The clinical features of MYOC glaucoma reflect the 
underlying mutation. The proband’s father (patient IV:8) was 
diagnosed with POAG at the age of 45. Glaucoma patients 
with Thr377Met usually have a disease of intermediate 
severity with an age at diagnosis of 41.6±13.2 years and a 
mean maximum IOP of 32.5±10 mmHg [6]. The same muta-
tion has been described in the isolated Croatian village of Veli 
Brgud, whose population has an unusually high prevalence 
of early-onset glaucoma [7]. The family of patient IV:8 was 
of Croatian background and came from a village 10 km from 
Veli Brgud. It is likely that they share a common genetic 
basis. Hewitt et al. previously reported that families from 
Greece, the USA, and Australia, all known to be of Greek or 
Macedonian ethnicity, shared a common haplotype [6].
The severity of phenotype in Gln368STOP carriers is 
variable, ranging from ocular hypertension to advanced 
glaucomatous neuropathy with severe visual field loss [8]. 
Figure 1. Pedigree chart with Gln368STOP and Thr377Met MYOC mutations. Round symbols indicate women; square symbols, men; 
diamond, gender unspecified; fully filled symbols, primary open-angle glaucoma; unfilled symbols, unaffected; diagonal line, deceased; 
arrow, proband.
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The mean maximum IOP for affected patients carrying 
Gln368STOP is 29.5±4.5 mmHg, and the mean age at diag-
nosis is 53±10.5 years [4]. The age at diagnosis may vary 
considerably; newly diagnosed patients ranging from age 32 
to 80 years have been described [4,8]. The proband’s mother 
carried Gln368STOP alone, and was unaffected at 63 years. 
As the penetrance at this age lies somewhere between 49% 
and 98%, this is not surprising [4].
Individuals with both Gln368STOP and Thr377Met 
appear more likely to develop ocular hypertension or glau-
coma from an earlier age than carrying either mutation alone 
would predict. The three affected individuals carrying both 
mutations were diagnosed between 25 and 35 years old. The 
penetrance at 25 years is low for both mutations (3% for 
Thr377Met and 1% for Gln368STOP) [4]. Juvenile affected 
carriers of Thr377Met have been described [9]. However, the 
father carrying Thr377Met in our pedigree was diagnosed 
with POAG at age 45, so we feel it is less likely Thr377Met 
al.one is responsible for the young age at diagnosis in the 
children. Detailed clinical and genotype data for affected 
members on the father’s side would be of considerable 
interest, but were unobtainable.
The only patient with both mutations without ocular 
hypertension was 34 years old at the time of review. It is 
highly probable she will develop glaucoma in the future, and 
therefore early treatment was offered and regular reviews 
scheduled.
To the best of our knowledge, there is only one other 
report of individuals carrying Thr377Met combined with 
another MYOC variant. In Greece, Thr377Met has been 
described in three individuals also carrying the Arg76Lys 
variant [10]. However, Arg76Lys is considered a neutral poly-
morphism [4], and in the Greek study, several control subjects 
carried this mutation [10]. Two patients were homozygous 
for Thr377Met, and demonstrated a more severe glaucoma 
phenotype than heterozygous cases for this variant [10]. 
This however was not the case for a patient homozygous for 
Gln368STOP, who showed no signs of glaucoma at the age 
of 49 [11].
Currently, the mechanism through which mutant 
MYOC protein contributes to the pathogenesis of glaucoma 
is unknown. Gln368STOP and Thr377Met are predicted to 
change the secondary structure of the MYOC protein [12]. 
Gln368STOP results in premature termination of protein 
synthesis [12]. Thr377Met is thought to cause the loss of 
phosphorylation of the Thr377 site by casein kinase II [10]. 
Both produce a Triton assay–insoluble protein [12]. The pres-
ence of these variants on opposing alleles would predict the 
assembly of aberrant heterodimeric protein, though further 
investigation is required to determine why this leads to a 
more severe phenotype.
Other rare compound heterozygote MYOC variants 
have been associated with glaucoma of earlier onset than 
predicted by a single mutation. An 11-year-old from Quebec 
with aggressive juvenile-onset glaucoma was found to be a 
compound Arg126Trp/Lys423Glu carrier [13]. In addition, 
a patient from eastern India compound heterozygote for 
Asn480Lys/Thr353Ile was diagnosed with glaucoma aged 
14 years [14], though the Thr353Ile mutation is of uncertain 
pathogenicity [4].
In summary, we have described the first known pedi-
gree containing compound heterozygotes for the two most 
common glaucoma-causing MYOC mutations, Gln368STOP 
and Thr377Met. Within this family, both mutations in combi-
nation predict a more severe phenotype than either in isola-
tion. Early identification of genetic risk in unaffected family 
members has strengthened the case for early treatment and 
monitoring. Our findings will assist clinicians in providing 
Figure 2. Fundus photographs for 
Patient V:6. The cup/disc ratio is 
0.5 in the right eye (A) and 0.4 in 
the left eye (B). Humphrey visual 
fields for the same patient show a 
right eye visual field defect due to 
previous panretinal photocoagula-
tion (C).
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more suitable treatments for affected individuals and appro-
priate preventive management for unaffected individuals who 
are compound heterozygotes for these two mutations. Our 
findings also provide resources for genetic counselors and 
clinicians to educate patients about their genetic risk profiles.
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